These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 9708408)

  • 21. Neutralizing antibodies to HIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain of HIV-1. NIAID AIDS Vaccine Clinical Trials Network.
    Belshe RB; Graham BS; Keefer MC; Gorse GJ; Wright P; Dolin R; Matthews T; Weinhold K; Bolognesi DP; Sposto R
    JAMA; 1994 Aug; 272(6):475-80. PubMed ID: 7913731
    [TBL] [Abstract][Full Text] [Related]  

  • 22. V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.
    Montefiori DC; Graham BS; Zhou J; Zhou J; Bucco RA; Schwartz DH; Cavacini LA; Posner MR
    J Clin Invest; 1993 Aug; 92(2):840-7. PubMed ID: 8349820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region.
    Srivastava IK; VanDorsten K; Vojtech L; Barnett SW; Stamatatos L
    J Virol; 2003 Feb; 77(4):2310-20. PubMed ID: 12551968
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens.
    Conley AJ; Conard P; Bondy S; Dolan CA; Hannah J; Leanza WJ; Marburg S; Rivetna M; Rusiecki VK; Sugg EE
    Vaccine; 1994 Apr; 12(5):445-51. PubMed ID: 8023553
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A dose-ranging study of a prototype synthetic HIV-1MN V3 branched peptide vaccine. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.
    Gorse GJ; Keefer MC; Belshe RB; Matthews TJ; Forrest BD; Hsieh RH; Koff WC; Hanson CV; Dolin R; Weinhold KJ; Frey SE; Ketter N; Fast PE
    J Infect Dis; 1996 Feb; 173(2):330-9. PubMed ID: 8568293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of neutralizing antibodies in rhesus macaques using V3 mimotope peptides.
    Hessell AJ; McBurney S; Pandey S; Sutton W; Liu L; Li L; Totrov M; Zolla-Pazner S; Haigwood NL; Gorny MK
    Vaccine; 2016 May; 34(24):2713-21. PubMed ID: 27102818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group.
    Belshe RB; Gorse GJ; Mulligan MJ; Evans TG; Keefer MC; Excler JL; Duliege AM; Tartaglia J; Cox WI; McNamara J; Hwang KL; Bradney A; Montefiori D; Weinhold KJ
    AIDS; 1998 Dec; 12(18):2407-15. PubMed ID: 9875578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.
    Newman MJ; Wu JY; Gardner BH; Anderson CA; Kensil CR; Recchia J; Coughlin RT; Powell MF
    Vaccine; 1997 Jun; 15(9):1001-7. PubMed ID: 9261947
    [TBL] [Abstract][Full Text] [Related]  

  • 29. International clinical trials of HIV vaccines: II. phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China.
    Li D; Forrest BD; Li Z; Xue P; Hanson CV; Duan S; Cheng H; Li M; Wang CY; Koff WC
    Asian Pac J Allergy Immunol; 1997 Jun; 15(2):105-13. PubMed ID: 9346275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differential role of V3-specific antibodies in neutralization assays involving primary and laboratory-adapted isolates of HIV type 1.
    Vancott TC; Polonis VR; Loomis LD; Michael NL; Nara PL; Birx DL
    AIDS Res Hum Retroviruses; 1995 Nov; 11(11):1379-91. PubMed ID: 8573396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Construction, biological activity, and immunogenicity of synthetic envelope DNA vaccines based on a primary, CCR5-tropic, early HIV type 1 isolate (BX08) with human codons.
    Corbet S; Vinner L; Hougaard DM; Bryder K; Nielsen HV; Nielsen C; Fomsgaard A
    AIDS Res Hum Retroviruses; 2000 Dec; 16(18):1997-2008. PubMed ID: 11153083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence of no change in V3 loop antibody recognition pattern in HIV type 1-infected Ethiopians between 1988 and 1993.
    Sherefa K; Sällberg M; Sönnerborg A
    AIDS Res Hum Retroviruses; 1994 Nov; 10(11):1551-6. PubMed ID: 7534097
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cross-subtype neutralizing antibodies induced in baboons by a subtype E gp120 immunogen based on an R5 primary human immunodeficiency virus type 1 envelope.
    VanCott TC; Mascola JR; Loomis-Price LD; Sinangil F; Zitomersky N; McNeil J; Robb ML; Birx DL; Barnett S
    J Virol; 1999 Jun; 73(6):4640-50. PubMed ID: 10233923
    [TBL] [Abstract][Full Text] [Related]  

  • 35. HIV type 1 V3 region primer-induced antibody suppression is overcome by administration of C4-V3 peptides as a polyvalent immunogen.
    Haynes BF; Moody MA; Heinley CS; Korber B; Millard WA; Scearce RM
    AIDS Res Hum Retroviruses; 1995 Feb; 11(2):211-21. PubMed ID: 7742036
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes.
    Chang JS; Choi MJ; Kim TY; Cho SY; Cheong HS
    Vaccine; 1999 Mar; 17(11-12):1540-8. PubMed ID: 10195791
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic and immunologic characterization of viruses infecting MN-rgp120-vaccinated volunteers.
    Berman PW; Gray AM; Wrin T; Vennari JC; Eastman DJ; Nakamura GR; Francis DP; Gorse G; Schwartz DH
    J Infect Dis; 1997 Aug; 176(2):384-97. PubMed ID: 9237703
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The multi-epitope polypeptide approach in HIV-1 vaccine development.
    Cano CA
    Genet Anal; 1999 Nov; 15(3-5):149-53. PubMed ID: 10596755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synthetic peptides containing T and B cell epitopes from human immunodeficiency virus envelope gp120 induce anti-HIV proliferative responses and high titers of neutralizing antibodies in rhesus monkeys.
    Hart MK; Palker TJ; Matthews TJ; Langlois AJ; Lerche NW; Martin ME; Scearce RM; McDanal C; Bolognesi DP; Haynes BF
    J Immunol; 1990 Oct; 145(8):2677-85. PubMed ID: 1698859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.